Skip to main content
SpringerLink
Log in

Highly Sensitive Enzymatic MWCNTs-Based Biosensors for Detection of Abiraterone in Human Serum

  • Published:
BioNanoScience Aims and scope Submit manuscript

Abstract

A highly sensitive enzymatic biosensor is successfully experimented for detection of abiraterone in human serum with significance in personalized medicine and point-of-care chemotherapy of patients with metastatic prostate cancer. The dynamic range and limit of the detection of the proposed biosensor coincide with the therapeutic range of abiraterone in circulatory system of patients (below 1 μM). An optimized label-free electrochemical biosensor was exploited in order to improve the performance of biosensor to detect low concentrations of abiraterone in human serum. Electroactive surface area has been increased by 4314 mm2 by multiwalled carbon nanotubes (MWCNTs) nanostructuring with respect to bare electrode to enhance the sensitivity. CYP3A4 protein was immobilized on MWCNTs as probe biomolecule. Electrochemical cyclic voltammetries demonstrated an inhibition effect on the CYP3A4, clearly observed as a diminished electrocatalytic activity of the enzyme. Dose-response behavior of biosensor in interaction with abiraterone in human serum samples is demonstrated that shows a dynamic range between zero and 1 μM and a detection limit of 230 nM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Malvezzi, M., Carioli, G., Bertuccio, P., Rosso, T., Boffetta, P., Levi, F., Vecchia, C. L., & Negri, E. (2016). European cancer mortality predictions for the year 2016 with focus on leukemias. Annals of Oncology. doi: 10.1093/annonc/mdw022.

    Google Scholar 

  2. Hakki, T., & Bernhardt, R. (2006). CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets. Pharmacology & Therapeutics, 111, 27–52. doi:10.1016/j.pharmthera.2005.07.006.

    Article  Google Scholar 

  3. Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics, 138, 103–141. doi:10.1016/j.pharmthera.2012.12.007.

    Article  Google Scholar 

  4. Acharya, M., Bernard, A., Gonzalez, M., Jiao, J., Vries, R. D., & Tran, N. (2012). Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemotherapy and Pharmacology, 69, 1583–1590. doi:10.1007/s00280-012-1865-3.

    Article  Google Scholar 

  5. Evans, W. E., & Relling, M. V. (2004). Moving towards individualized medicine with pharmacogenomics. Nature, 429, 464–468. doi:10.1038/nature02626.

    Article  Google Scholar 

  6. Weinshilboum, R., & Wang, L. (2004). Pharmacogenomics: bench to bed-side. Nature Reviews. Drug Discovery, 3, 739–748. doi:10.1038/nrd1497.

    Article  Google Scholar 

  7. Aliakbarinodehi, N., Taurino, I., Pravin, J., Tagliaferro, A., Piccinini, G., De, M. G., & Carrara, S. (2014). Electrochemical nanostructured biosensors: carbon nanotubes versus conductive and semi-conductive nanoparticles. Chemical Papers, 69, 134–142. doi:10.1515/chempap-2015-0004.

    Google Scholar 

  8. Aliakbarinodehi, N., Micheli, G.D., Carrara, S. (2015) Optimized electro-chemical detection of anti-cancer drug by carbon nanotubes or gold nanoparticles. In: Res. Microelectron. Electron. PRIME 2015 11th Conf. PhD. pp 25–28.

  9. Aliakbarinodehi, N., De Micheli, G., & Carrara, S. (2016). Enzymatic and nonenzymatic electrochemical interaction of abiraterone (antiprostate cancer drug) with multiwalled carbon nanotube bioelectrodes. Analytical Chemistry, 88, 9347–9350. doi:10.1021/acs.analchem.6b02747.

    Article  Google Scholar 

  10. Asturias-Arribas, L., Alonso-Lomillo, M. A., Domínguez-Renedo, O., & Arcos-Martínez, M. J. (2013). Electrochemical determination of cocaine using screen-printed cytochrome P450 2B4 based biosensors. Talanta, 105, 131–134. doi:10.1016/j.talanta.2012.11.078.

    Article  Google Scholar 

  11. Carrara, S., Cavallini, A., Erokhin, V., & De Micheli, G. (2011). Multi-panel drugs detection in human serum for personalized therapy. Biosens Bio-electron, 26, 3914–3919. doi:10.1016/j.bios.2011.03.009.

    Article  Google Scholar 

  12. Baj-Rossi, C., Rezzonico Jost, T., Cavallini, A., Grassi, F., De Micheli, G., & Carrara, S. (2014). Continuous monitoring of naproxen by a cytochrome P450-based electrochemical sensor. Biosensors & Bioelectronics, 53, 283–287. doi:10.1016/j.bios.2013.09.058.

    Article  Google Scholar 

  13. Baj-Rossi, C., Micheli, G. D., & Carrara, S. (2012). Electrochemical detection of anti-breast-cancer agents in human serum by cytochrome P450-coated carbon nanotubes. Sensors, 12, 6520–6537. doi:10.3390/s120506520.

    Article  Google Scholar 

  14. Sun, P., & Wu, Y. (2013). An amperometric biosensor based on human cytochrome P450 2C9 in polyacrylamide hydrogel films for bisphenol A determination. Sens Actuators B Chem, 178, 113–118. doi:10.1016/j.snb.2012.12.055.

    Article  Google Scholar 

  15. Wu, Y., Liu, X., Zhang, L., & Wang, C. (2011). An amperometric biosensor based on rat cytochrome p450 1A1 for benzo[a]pyrene determination. Biosensors & Bioelectronics, 26, 2177–2182. doi:10.1016/j.bios.2010.09.027.

    Article  Google Scholar 

  16. Müller M, Agarwal N, Kim J (2016) A cytochrome P450 3A4 biosensor based on generation 4.0 PAMAM dendrimers for the detection of caffeine. Biosensors 6:44. doi: 10.3390/bios6030044

  17. Asturias-Arribas, L., Alonso-Lomillo, M. A., Domínguez-Renedo, O., & Arcos-Martínez, M. J. (2011). CYP450 biosensors based on screen-printed car-bon electrodes for the determination of cocaine. Analytica Chimica Acta, 685, 15–20. doi:10.1016/j.aca.2010.11.006.

    Article  Google Scholar 

  18. Armbruster, D. A., & Pry, T. (2008). Limit of blank, limit of detection and limit of quantitation. Clinical Biochemist Reviews, 29, S49–S52.

    Google Scholar 

Download references

Acknowledgements

This research was partly funded by the European Commission FP7 Program through the Marie Curie Initial Training Network PROSENSE (grant no. 317420, 2012-2016) and partly by H2020-ERC-2014-ADG 669354 CyberCare.

Author Contributions

The manuscript was written through the contributions of all authors. All authors have given approval to the final version of the manuscript.

Author information

Authors and Affiliations

  1. Integrated Systems Laboratory, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland

    Nima Aliakbarinodehi, Giovanni De Micheli & Sandro Carrara

Authors
  1. Nima Aliakbarinodehi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni De Micheli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandro Carrara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nima Aliakbarinodehi.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aliakbarinodehi, N., De Micheli, G. & Carrara, S. Highly Sensitive Enzymatic MWCNTs-Based Biosensors for Detection of Abiraterone in Human Serum. BioNanoSci. 8, 675–679 (2018). https://doi.org/10.1007/s12668-017-0393-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12668-017-0393-3

Keywords

Search

Navigation